Peter Lurie
Peter Lurie has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Sidney M. Wolfe
3 shared publicationsSidney M Wolfe
2 shared publications- Alexander R. Stine
Department of Earth & Climate Sciences, San Francisco State University, San Francisco, USA
1 shared publication Amer Ardati
Public Citizen's Health Research Group, NW Washington, District Columbia, USA
1 shared publicationAsa L Tapley
1 shared publicationBenita Marcus
1 shared publication
Latest Publications
- 1 January 2009
- Vol. 19 (1) , 121-36
Survey of state medical and osteopathy board disciplinary web sites in 2006.
We sought to describe doctor disciplinary information provided on the web sites of state medical and osteopathic boards. Information collected included state board, hospital and federal government actions, as well as malpractice judgments and settlements and conviction information. Web sites were also assessed for user-friendliness, primarily their searchability. Expert reviewers provided weights for these elements, yielding a 100-point score. The median score was 42.4 (range: 12.3-83.7). All sites provided physician profile information and 92% offer at least some board disciplinary information. Thirty-two percent provided non-state disciplinary information and 13 states' web sites were not searchable. We conclude that some boards provide very limited information and many do not facilitate efficient consumer access. The findings were released on Public Citizen's web site on October 17, 2006.
- 1 January 2009
- Vol. 19 (1) , 121-36
Survey of state medical and osteopathy board disciplinary web sites in 2006.
We sought to describe doctor disciplinary information provided on the web sites of state medical and osteopathic boards. Information collected included state board, hospital and federal government actions, as well as malpractice judgments and settlements and conviction information. Web sites were also assessed for user-friendliness, primarily their searchability. Expert reviewers provided weights for these elements, yielding a 100-point score. The median score was 42.4 (range: 12.3-83.7). All sites provided physician profile information and 92% offer at least some board disciplinary information. Thirty-two percent provided non-state disciplinary information and 13 states' web sites were not searchable. We conclude that some boards provide very limited information and many do not facilitate efficient consumer access. The findings were released on Public Citizen's web site on October 17, 2006.
- 7 June 2007
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (23) , 2421-2422
Hepatitis E Vaccine
The study by Shrestha et al. (March 1 issue),1 which evaluated a vaccine for hepatitis E virus (HEV), represents a major advance but continues to raise ethical concerns. The trial of the HEV recombinant protein (rHEV) vaccine, conducted by the U.S. military and GlaxoSmithKline, was forced out of a Nepalese community after protests about whether residents would have access to the vaccine after the trial.2 The study was subsequently relocated to the Nepalese Army. The consent of soldiers may be “unduly influenced . . . by fear of disapproval or retaliation if they refuse,”3 which is why research involving soldiers should take place only if it “could not be carried out equally well with less vulnerable subjects.”3 Indeed, the subjects may have been placed at needless risk, because the vaccine may not be developed. GlaxoSmithKline stated that a third party would need to develop the vaccine, given its low profit value.4 It is crucial that phase 3 trials take place soon and that thereafter any viable vaccine be made accessible, particularly to communities that undertook the risk of testing.
- 7 June 2007
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (23) , 2421-2422
Hepatitis E Vaccine
The study by Shrestha et al. (March 1 issue),1 which evaluated a vaccine for hepatitis E virus (HEV), represents a major advance but continues to raise ethical concerns. The trial of the HEV recombinant protein (rHEV) vaccine, conducted by the U.S. military and GlaxoSmithKline, was forced out of a Nepalese community after protests about whether residents would have access to the vaccine after the trial.2 The study was subsequently relocated to the Nepalese Army. The consent of soldiers may be “unduly influenced . . . by fear of disapproval or retaliation if they refuse,”3 which is why research involving soldiers should take place only if it “could not be carried out equally well with less vulnerable subjects.”3 Indeed, the subjects may have been placed at needless risk, because the vaccine may not be developed. GlaxoSmithKline stated that a third party would need to develop the vaccine, given its low profit value.4 It is crucial that phase 3 trials take place soon and that thereafter any viable vaccine be made accessible, particularly to communities that undertook the risk of testing.
- 1 December 2006
- Published by Elsevier in The Lancet
- Vol. 368 (9554) , 2210
Suboptimum use of FDA drug advisory committees
- 1 December 2006
- Published by Elsevier in The Lancet
- Vol. 368 (9554) , 2210
Suboptimum use of FDA drug advisory committees
- 30 October 2006
- Vol. 8 (4) , 22
Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
- 30 October 2006
- Vol. 8 (4) , 22
Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
- Open Access
- 26 April 2006
- Published by American Medical Association (AMA) in JAMA
- Vol. 295 (16) , 1921-1928
Financial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings
The Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA) approves 25 to 30 new chemical entities each year, often relying in its decision making on the advice of advisory committees composed of outside scientific experts. In 2001, 21% of these approvals were preceded by an advisory committee meeting.1
- 26 April 2006
- Published by American Medical Association (AMA) in JAMA
- Vol. 295 (16) , 1921-1928
Open AccessFinancial Conflict of Interest Disclosure and Voting Patterns at Food and Drug Administration Drug Advisory Committee Meetings
The Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA) approves 25 to 30 new chemical entities each year, often relying in its decision making on the advice of advisory committees composed of outside scientific experts. In 2001, 21% of these approvals were preceded by an advisory committee meeting.1
- Open Access
- 23 February 2006
- Published by Springer Nature in Environmental Health
- Vol. 5 (1) , 5
Selected science: an industry campaign to undermine an OSHA hexavalent chromium standard
While exposure to hexavalent chromium (Cr(VI)) has been associated with increased lung cancer risk for more than 50 years, the chemical is not currently regulated by the U.S. Occupational Safety and Health Administration (OSHA) on the basis of its carcinogenicity. The agency was petitioned in 1993 and sued in 1997 and 2002 to lower the workplace Cr(VI) exposure limit, resulting in a court order to issue a final standard by February 2006. Faced with the threat of stronger regulation, the chromium industry initiated an effort to challenge the scientific evidence supporting a more protective standard. This effort included the use of "product defense" consultants to conduct post hoc analyses of a publicly-funded study to challenge results viewed unfavorably by the industry. The industry also commissioned a study of the mortality experience of workers at four low-exposure chromium plants, but did not make the results available to OSHA in a timely manner, despite multiple agency requests for precisely these sorts of data. The commissioned study found a statistically significant elevation in lung cancer risk among Cr(VI)-exposed workers at levels far below the current standard. This finding changed when the multi-plant cohort was divided into two statistically underpowered components and then published separately. The findings of the first paper published have been used by the chromium industry to attempt to slow OSHA's standard setting process. The second paper was withheld from OSHA until it was accepted for publication in a scientific journal, after the rulemaking record had closed. Studies funded by private sponsors that seek to influence public regulatory proceedings should be subject to the same access and reporting provisions as those applied to publicly funded science. Parties in regulatory proceedings should be required to disclose whether the studies were performed by researchers who had the right to present their findings without the sponsor's consent or influence, and to certify that all relevant data have been submitted to the public record, whether published or not.
- 23 February 2006
- Published by Springer Nature in Environmental Health
- Vol. 5 (1) , 5
Open AccessSelected science: an industry campaign to undermine an OSHA hexavalent chromium standard
While exposure to hexavalent chromium (Cr(VI)) has been associated with increased lung cancer risk for more than 50 years, the chemical is not currently regulated by the U.S. Occupational Safety and Health Administration (OSHA) on the basis of its carcinogenicity. The agency was petitioned in 1993 and sued in 1997 and 2002 to lower the workplace Cr(VI) exposure limit, resulting in a court order to issue a final standard by February 2006. Faced with the threat of stronger regulation, the chromium industry initiated an effort to challenge the scientific evidence supporting a more protective standard. This effort included the use of "product defense" consultants to conduct post hoc analyses of a publicly-funded study to challenge results viewed unfavorably by the industry. The industry also commissioned a study of the mortality experience of workers at four low-exposure chromium plants, but did not make the results available to OSHA in a timely manner, despite multiple agency requests for precisely these sorts of data. The commissioned study found a statistically significant elevation in lung cancer risk among Cr(VI)-exposed workers at levels far below the current standard. This finding changed when the multi-plant cohort was divided into two statistically underpowered components and then published separately. The findings of the first paper published have been used by the chromium industry to attempt to slow OSHA's standard setting process. The second paper was withheld from OSHA until it was accepted for publication in a scientific journal, after the rulemaking record had closed. Studies funded by private sponsors that seek to influence public regulatory proceedings should be subject to the same access and reporting provisions as those applied to publicly funded science. Parties in regulatory proceedings should be required to disclose whether the studies were performed by researchers who had the right to present their findings without the sponsor's consent or influence, and to certify that all relevant data have been submitted to the public record, whether published or not.
- 22 March 2005
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 14 (4) , 287
Statin-associated rhabdomyolysis
- 22 March 2005
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 14 (4) , 287
Statin-associated rhabdomyolysis
- 1 March 2005
- Published by Elsevier in The Lancet
- Vol. 365 (9465) , 1117-1119
US exceptionalism comes to research ethics
- 1 March 2005
- Published by Elsevier in The Lancet
- Vol. 365 (9465) , 1117-1119
US exceptionalism comes to research ethics
- 15 October 2002
- Published by Wiley in American Journal of Industrial Medicine
- Vol. 42 (5) , 378-383
Continuing exposure to hexavalent chromium, a known lung carcinogen: An analysis of OSHA compliance inspections, 1990–2000
Background Hexavalent chromium is widely recognized to be a lung carcinogen. However, the U.S. Occupational Safety and Health Administration (OSHA) has failed to reduce the permissible exposure limit (PEL), despite having acknowledged in 1994 that the current limit is too high. In 1993, Public Citizen and the Paper, Allied-Industrial, Chemical and Energy Workers International Union (PACE) petitioned to lower the PEL from the current 100 μg/m3 to 0.5 μg/m3 as an 8-hr time-weighted average (TWA). Methods To assess industry compliance with the current PEL, and to determine the feasibility of achieving the proposed lower limit of 0.5 μg/m3, we conducted a secondary data analysis of OSHA's Integrated Management Information System (IMIS) database. This database contains 813 measurements of hexavalent chromium exposure from inspections performed during the years 1990–2000. Results There was a statistically significant decline in the annual number of measurements over the study period from 127 in 1990 to 67 in 2000 (F = 0.0009; linear regression). The median TWA measurement was 10 μg/m3 (range: 0.01–13,960 μg/m3) and the median ceiling measurement was 40.5 μg/m3 (range: 0.25–25,000 μg/m3). Neither median TWA nor median ceiling exposures (if hexavalent chromium was detected) declined significantly during the study period (F = 0.065 and 0.57, respectively). Overall, 13.7% of TWA measurements were at or below the Public Citizen/PACE proposed standard; 65.0% were between the Public Citizen/PACE proposal and the current OSHA PEL; and 21.3% exceeded the OSHA PEL. Compared to OSHA measurements, state measurements were less likely to detect hexavalent chromium (40.2% vs. 52.1%; P = 0.0007; chi-square) and less likely to issue any citation (9.3% vs. 19.1%; P = 0.0003), including citations for overexposure if the exposure exceeded the PEL (54.8% vs. 78.8%; P = 0.012). Conclusions U.S. workers continue to be exposed to dangerously high hexavalent chromium levels, but low exposure levels were found in some industries. Further investigations should examine whether state plans provide weaker enforcement than federal OSHA. Am. J. Ind. Med. 42:378–383, 2002.
- 15 October 2002
- Published by Wiley in American Journal of Industrial Medicine
- Vol. 42 (5) , 378-383
Continuing exposure to hexavalent chromium, a known lung carcinogen: An analysis of OSHA compliance inspections, 1990–2000
Background Hexavalent chromium is widely recognized to be a lung carcinogen. However, the U.S. Occupational Safety and Health Administration (OSHA) has failed to reduce the permissible exposure limit (PEL), despite having acknowledged in 1994 that the current limit is too high. In 1993, Public Citizen and the Paper, Allied-Industrial, Chemical and Energy Workers International Union (PACE) petitioned to lower the PEL from the current 100 μg/m3 to 0.5 μg/m3 as an 8-hr time-weighted average (TWA). Methods To assess industry compliance with the current PEL, and to determine the feasibility of achieving the proposed lower limit of 0.5 μg/m3, we conducted a secondary data analysis of OSHA's Integrated Management Information System (IMIS) database. This database contains 813 measurements of hexavalent chromium exposure from inspections performed during the years 1990–2000. Results There was a statistically significant decline in the annual number of measurements over the study period from 127 in 1990 to 67 in 2000 (F = 0.0009; linear regression). The median TWA measurement was 10 μg/m3 (range: 0.01–13,960 μg/m3) and the median ceiling measurement was 40.5 μg/m3 (range: 0.25–25,000 μg/m3). Neither median TWA nor median ceiling exposures (if hexavalent chromium was detected) declined significantly during the study period (F = 0.065 and 0.57, respectively). Overall, 13.7% of TWA measurements were at or below the Public Citizen/PACE proposed standard; 65.0% were between the Public Citizen/PACE proposal and the current OSHA PEL; and 21.3% exceeded the OSHA PEL. Compared to OSHA measurements, state measurements were less likely to detect hexavalent chromium (40.2% vs. 52.1%; P = 0.0007; chi-square) and less likely to issue any citation (9.3% vs. 19.1%; P = 0.0003), including citations for overexposure if the exposure exceeded the PEL (54.8% vs. 78.8%; P = 0.012). Conclusions U.S. workers continue to be exposed to dangerously high hexavalent chromium levels, but low exposure levels were found in some industries. Further investigations should examine whether state plans provide weaker enforcement than federal OSHA. Am. J. Ind. Med. 42:378–383, 2002.